These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Protease-inhibitor boosting in the treatment-experienced patient. Gallant JE AIDS Rev; 2004; 6(4):226-33. PubMed ID: 15700621 [TBL] [Abstract][Full Text] [Related]
6. A review of low-dose ritonavir in protease inhibitor combination therapy. Cooper CL; van Heeswijk RP; Gallicano K; Cameron DW Clin Infect Dis; 2003 Jun; 36(12):1585-92. PubMed ID: 12802760 [TBL] [Abstract][Full Text] [Related]
7. Fosamprenavir calcium plus ritonavir for HIV infection. Torres HA; Arduino RC Expert Rev Anti Infect Ther; 2007 Jun; 5(3):349-63. PubMed ID: 17547501 [TBL] [Abstract][Full Text] [Related]
8. Saquinavir/low-dose ritonavir: its use in HIV infection. Johnson M; Peters B AIDS Rev; 2003; 5(1):44-51. PubMed ID: 12875107 [TBL] [Abstract][Full Text] [Related]
9. Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection. Sahali S; Chaix ML; Delfraissy JF; Ghosn J AIDS Rev; 2008; 10(1):4-14. PubMed ID: 18385776 [TBL] [Abstract][Full Text] [Related]
10. Ritonavir-boosted protease inhibitors, Part 1: strategies for balancing efficacy with effects on lipids. Cohen CJ AIDS Read; 2005 Sep; 15(9):462-5, 470-1, 474, 477. PubMed ID: 16170876 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors. Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K; HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686 [TBL] [Abstract][Full Text] [Related]
12. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. Haubrich R; Berger D; Chiliade P; Colson A; Conant M; Gallant J; Wilkin T; Nadler J; Pierone G; Saag M; van Baelen B; Lefebvre E; AIDS; 2007 Mar; 21(6):F11-8. PubMed ID: 17413685 [TBL] [Abstract][Full Text] [Related]
13. Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections. Tan D; Walmsley S Expert Rev Anti Infect Ther; 2007 Feb; 5(1):13-28. PubMed ID: 17266450 [TBL] [Abstract][Full Text] [Related]
14. Tipranavir: new drug. HIV protease inhibitor. A last resort. Prescrire Int; 2006 Dec; 15(86):217-9. PubMed ID: 17167925 [TBL] [Abstract][Full Text] [Related]
15. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. Bierman WF; van Agtmael MA; Nijhuis M; Danner SA; Boucher CA AIDS; 2009 Jan; 23(3):279-91. PubMed ID: 19114854 [TBL] [Abstract][Full Text] [Related]
16. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children. Rudin C; Burri M; Shen Y; Rode R; Nadal D; ; Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386 [TBL] [Abstract][Full Text] [Related]
17. Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program. Pérez-Elias MJ; Sánchez-Conde M; Soriano V; Mallolas J; Luque I; Rodríguez-Alcántara F; Enferm Infecc Microbiol Clin; 2009 Jan; 27(1):28-32. PubMed ID: 19218000 [TBL] [Abstract][Full Text] [Related]
18. Ritonavir-boosted protease inhibitors, Part 2: cardiac implications of lipid alterations. Cohen CJ AIDS Read; 2005 Oct; 15(10):528-32, 537-8. PubMed ID: 16265768 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E; Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947 [TBL] [Abstract][Full Text] [Related]